AMD

EYP-1901 shows promising results in reducing treatment burden and improving vision in neovascular age-related macular degeneration, as revealed at EURETINA 2025.

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.

The presence of AMD predicted an increased risk of all-cause and CVD mortality in patients with a high risk of CVD, even in the early stages of AMD.

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

Roche reveals promising results for Vabysmo in treating eye diseases, showcasing significant vision improvements and safety in recent clinical trials.

The acquisition includes the noninvasive Valeda PBM device for the treatment of early and intermediate dry age-related macular degeneration.

Ashvattha Therapeutics reveals phase 2 results for migaldendranib, showing significant vision improvements and reduced injection needs in retinal disease patients.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.

OpZira Inc. launches innovative ophthalmic diagnostic tools, enhancing early detection and monitoring of ocular diseases for improved patient outcomes.

Outlook Therapeutics seeks FDA clarity on ONS-5010 after a complete response letter, aiming to address efficacy concerns for wet AMD treatment.

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company after the COAST trial failed to meet its primary end point.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

4D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for potential market approval.

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

The Portal study is a long-term extension of the phase 3 Archway study

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.